[Diagnosis and satisfactory surgical treatment of a jejunal stromal tumor].
GIST is the most common mesenchymal tumor of the gastrointestinal tract. The discovery of KIT proto-oncogene mutations in the pathogenesis of this tumor, and the development of imatinib mesylate, a specific inhibitor of KIT tyrosine kinase function have revolutionized the treatment of GIST. We present the clinical case of a patient with an upper digestive bleeding secondary to a jejunal GIST. Therapeutic options are highlighted.